

## Supplementary Information

### Growth vector elaboration of fragments: regioselective functionalization of 5-hydroxy-6-azaindazole and 3-hydroxy-2,6-naphthyridine

Paulo Eliandro da Silva Júnior,<sup>a</sup> Shaiani Maria Gil de Melo,<sup>a</sup> Murilo Helder de Paula,<sup>a</sup> Ricardo Vessecchi,<sup>b</sup> Till Opatz,<sup>c</sup> James E. H. Day,<sup>e</sup> A. Ganesan,<sup>d\*</sup> Flavio da Silva Emery.<sup>a\*</sup>

<sup>a.</sup> Faculty of Pharmaceutical Sciences of Ribeirão Preto, Department of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto 14040-903, Brazil.

<sup>b.</sup> Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900, Ribeirão Preto, SP, 14040-901, Brazil.

<sup>c.</sup> Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10–14, Mainz 55128, Germany.

<sup>d.</sup> School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, United Kingdom.

<sup>e.</sup> Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom.


\*Email: flavioemery@usp.br, a.ganesan@uea.ac.uk

#### TABLE OF CONTENTS:

1. Solution Gibbs energies ( $G_{sol}$ ).....	S2
2. Synthetic Procedures for compounds already published in the literature.....	S5
3. NMR-spectra.....	S12

## 1. SOLUTION GIBBS ENERGIES ( $G_{sol}$ )


pKa values were computed using the following isodesmic reaction:



pKa values were obtained in DMSO solvent system, performed by PCM model using single-point calculations with B3LYP/6-311++G(d,p)//B3LYP/6-31+G(d,p) model. The solvation Gibbs energies were obtained to deprotonation reaction using pyridine as reference compound.

Gibbs energies in solution for neutral and deprotonated species. All the values were obtained in B3LYP/6-311++G(d,p) using DMSO in PCM. Values in Hartree.

In order to predict the regioselectivity, we employed density-functional theory (DFT) calculations as previously done in several studies to describe radical functionalization in heterocycle compounds.<sup>1</sup> To estimate the reactivity of the hydroxypyridine moiety, pKa values were calculated using isodesmic reactions<sup>2-7</sup> in dimethyl sulfoxide (DMSO) using the proteochemometric (PCM) model and single-point calculations at the B3LYP/6-311++G(d,p) level using Gaussian 03.<sup>8-16</sup> The solvation Gibbs energies were obtained for deprotonation reactions using pyridine as a reference compound (see the Supporting Information). The most acidic C–H was found to be next to the pyridone oxygen and pyrazole nitrogen (Figure 2).



**Figure 1.** Calculated pKa values in DMSO for heterocycles **1** and **2** using DFT (PCM/B3LYP/6-311++G(d,p)/B3LYP/6-31+G(d,p)). Arrows indicate the predicted reactive sites for C–H activation.

### References:

1. **A)** Cernak, T.; Dykstra, K. D.; Tyagarajan, S.; Vachal, P.; Krska, S. W. The Medicinal Chemist's Toolbox for Late Stage Functionalization of Drug-like Molecules. *Chem. Soc. Rev.* 2016, **45** (3), 546–576. **B)** Dong, Y.; Zhang, X.; Chen, J.; Zou, W.; Lin, S.; Xu, H. Switching the Site-Selectivity of C–H Activation in Aryl Sulfonamides Containing Strongly Coordinating N-Heterocycles. *Chem. Sci.* 2019, **10** (38), 8744–8751.
2. Shen, K.; Fu, Y.; Li, J.-N.; Liu, L.; Guo, Q.-X. What are the pKa values of C–H bonds in aromatic heterocyclic compounds in DMSO? *Tetrahedron* 2007, **63** (7), 1568-1576.
3. da Silva, G.; Chen, C. C.; Bozzelli, J. W. Bond dissociation energy of the phenol OH bond from ab initio calculations. *Chem. Phys. Lett.* 2006, **424** (1-3), 42-45.
4. da Silva, G.; Kim, C. H.; Bozzelli, J. W. Thermodynamic Properties (Enthalpy, Bond Energy, Entropy, and Heat Capacity) and Internal Rotor Potentials of Vinyl Alcohol, Methyl Vinyl Ether, and Their Corresponding Radicals. *J. Phys. Chem. A* 2006, **110** (25), 7925-7934.
5. Casasnovas, R.; Fernandez, D.; Ortega-Castro, J.; Frau, J.; Donoso, J.; Munoz, F. Avoiding gas-phase calculations in theoretical pKa predictions. *Theor. Chem. Acc.* 2011, **130** (1), 1-13.
6. Sastre, S.; Casasnovas, R.; Munoz, F.; Frau, J. Isodesmic reaction for pKa calculations of common organic molecules. *Theor. Chem. Acc.* 2013, **132** (2), 1310-1317.
7. Chevallier, F.; Blin, T.; Nagaradjja, E.; Lassagne, F.; Roisnel, T.; Halauko, Y. S.; Matulis, V. E.; Ivashkevich, O. A.; Mongin, F. Deproto-metallation and computed CH acidity of 2-aryl-1,2,3-triazoles. *Org. Biomol. Chem.* 2012, **10**, 4878-4885.


8. Shen, K.; Fu, Y.; Li, J.-N.; Liu, L.; Guo, Q.-X. What are the pKa values of C–H bonds in aromatic heterocyclic compounds in DMSO? *Tetrahedron* 2007, **63** (7), 1568-1576.
9. da Silva, G.; Chen, C. C.; Bozzelli, J. W. Bond dissociation energy of the phenol OH bond from ab initio calculations. *Chem. Phys. Lett.* 2006, **424** (1-3), 42-45.
10. da Silva, G.; Kim, C. H.; Bozzelli, J. W. Thermodynamic Properties (Enthalpy, Bond Energy, Entropy, and Heat Capacity) and Internal Rotor Potentials of Vinyl Alcohol, Methyl Vinyl Ether, and Their Corresponding Radicals. *J. Phys. Chem. A* 2006, **110** (25), 7925-7934.
11. Casanovas, R.; Fernandez, D.; Ortega-Castro, J.; Frau, J.; Donoso, J.; Munoz, F. Avoiding gas-phase calculations in theoretical pKa predictions. *Theor. Chem. Acc.* 2011, **130** (1), 1-13.
12. Sastre, S.; Casanovas, R.; Munoz, F.; Frau, J. Isodesmic reaction for pKa calculations of common organic molecules. *Theor. Chem. Acc.* 2013, **132** (2), 1310-1317.
13. Chevallier, F.; Blin, T.; Nagaradja, E.; Lassagne, F.; Roisnel, T.; Halauko, Y. S.; Matulis, V. E.; Ivashkevich, O. A.; Mongin, F. Deproto-metallation and computed CH acidity of 2-aryl-1,2,3-triazoles. *Org. Biomol. Chem.* 2012, **10**, 4878-4885.
14. Tomasi, J.; Mennucci, B.; Cammi, R. Quantum Mechanical Continuum Solvation Models. *Chem. Rev.* 2005, **105** (8), 2999-3094.
15. Tomasi, J.; Persico, M. Molecular Interactions in Solution: An Overview of Methods Based on Continuous Distributions of the Solvent. *Chem. Rev.* 1994, **94** (7), 2027-2094.
16. Gaussian 03, R. C., M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. A. Montgomery, Jr., T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam, S. S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, C. Gonzalez, and J. A. Pople, Gaussian, Inc., Wallingford CT, 2004.

1	Gsol	2	Gsol
	-471,258395	Neutral 	-493,339949
dp1 	-470,717020	dp1 	-492,791189
dp2 	-470,717400	dp2 	-492,800921
dp3 	-470,773624	dp3 	-492,795532
dp4 	-470,716286	dp4 	-492,796742
dpOH 	-470,775542	dp5 	-492,785520
		dpOH 	-492,864918
		Pyridine 	-248,356883
			-247,808111

## 2. SYNTHETIC PROCEDURES – for compounds already published in the literature


All solvents used for extraction and chromatography procedures were used as received from commercial suppliers without further purification. All reagents were purchased and used as received unless otherwise noted. The physicochemical properties were calculated using Vortex (2015.07.42634, Dotmatics Ltd.) and MarvinSketch (15.7.20, 2015, ChemAxon).

### 1*H*-Pyrazolo[3,4-*c*]pyridin-5-ol (**1**)




To a solution of 4-methyl-5-nitropyridin-2-ol **3** (3.52 g, 22.83 mmol) in methanol (500 mL) was added Raney® 2800 nickel (excess, 15 mL of the slurry in water) at room temperature. This suspension was purged with hydrogen and stirred for 5 hours. The solid material was filtered off and the filtrate was concentrated. Then, acetic anhydride (80 mL, 846 mmol) was added to the crude solid, the reaction was stirred for 17 hours at room temperature under nitrogen atmosphere. Then, NaNO<sub>2</sub> (7.879 g, 114.2 mmol) was added to the mixture at vigorous stirring at room temperature for 3 hours and after this time, the mixture was heated to 90°C for 3 hours. The insoluble material was filtered off and washed with EtOAc (3x20 mL), the solvent was removed under reduced pressure to give brown solid as the crude product. 1 N HCl (100 mL) aqueous solution was added to crude product and it was stirred for 17 hours at room temperature. The solvent was distilled off under reduced pressure resulting in the crude hydrochloride form. The product was purified by flash chromatography (dichloromethane to remove impurities, and then methanol – dichloromethane, 4:1), to yield an orange solid, 3.23 g (82%). <sup>1</sup>H NMR (400 MHz, XXXYridin-*d*<sub>4</sub>) δ 8.89 (s, 1H), 8.30 (s, 1H), 7.44 (s, 1H). <sup>13</sup>C NMR (101 MHz, Methanol-*d*<sub>4</sub>) δ 152.6, 135.1, 134.2, 133.0, 127.5, 99.5. IR (solid, ν/cm<sup>-1</sup>): 3154, 1656, 1537, 1402, 607. HRMS (EI) *m/z* [M+H]<sup>+</sup> calcd for C<sub>6</sub>H<sub>6</sub>N<sub>3</sub>O<sup>+</sup>: 136.0505; found: 136.0506. The obtained spectroscopic data are in accordance with those reported in the literature.<sup>1</sup>

### 3-iodopyridine (**7**)




To a solution of p-TsOH.H<sub>2</sub>O (244.5 g, 1.28 mol) in MeCN (2 L) was added **6** (40.1 g, 0.42 mol). The resulting suspension was cooled to 10-15 °C, then a solution of NaNO<sub>2</sub> (58.6 g, 0.85 mmol) and KI (176.3 g, 1.06 mol) in H<sub>2</sub>O (200 mL) was added. The reaction mixture was stirred for 10 min, then allowed to stir at 20 °C for 1 hour. To the reaction mixture was then added a solution of NaHCO<sub>3</sub> aq. (1M, until pH = 9-10) and Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (2M, 100 mL). The reaction was extracted with EtOAc (3 x 250 mL) and purified by flash chromatography (ethyl acetate – dichloromethane, 1:4), resulting in 55g of **7** (64%) as a pale solid. The obtained spectroscopic data are in accordance with those reported in the literature.<sup>2</sup>

### Ethyl-2-(pyridinyl)-3-acetate (**8**)




A mixture of **7** (57.2 g, 0.278 mol), ethyl acetoacetate (72 mL, 0.834 mmol), CuI (5.2 g, 10 mol%), K<sub>3</sub>PO<sub>4</sub> (175.4 g, 0.834 mol) and ethanol (48 mL, 0.834 mol) in DMSO (200 mL) was stirred under N<sub>2</sub> atmosphere at 80 °C for 17 h. After completion of the reaction, the mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 x 100 mL). The pure product was obtained by flash column chromatography (methanol – dichloromethane, 1:19), resulting in 45.9 g of **8** (78%) as an orange oil. The obtained spectroscopic data are in accordance with those reported in the literature.<sup>3</sup>

*3-(2-ethoxy-2-oxoethyl)pyridine 1-oxide (8.1)*




A solution of mCPBA (61 mmol, 10.5 g) in chloroform (100 mL) was added dropwise to a stirring solution of **8** (41 mmol, 6.82g) in methanol (50 ml), at room temperature. The reaction was followed by LCMS. After 4 hours the reaction was completed, the solvent was removed under reduced pressure and then dissolved in 2M Na<sub>2</sub>CO<sub>3</sub> solution and extracted with chloroform (3x 20 mL). The organic layer was dried with MgSO<sub>4</sub> and the solvent removed under reduced pressure to give 6,59 g of **8** (88%) as a pale crystal. M.p. 103 °C. The obtained spectroscopic data are in accordance with those reported in the literature.<sup>1</sup>

*1-ethoxy-3-(2-ethoxy-2-oxoethyl)pyridinium iodide (8.2)*




Iodoethane (10 mL, 134 mmol) was added to **8.1** (6.48 g, 35 mmol), the mixture was stirred for 6 hours at 40 °C under nitrogen atmosphere. The mixture was concentrated under reduced pressure, resulting in 9.79 g (83%) of crude product **8.2** as a dark orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.24 (t, *J* = 5 Hz, 3H), 3,57 (s, 2H), 4.36 (q, *J* = 5Hz, 2H), 7.26 (s, 1H), 7.26 (s, 1H), 8.19 (s, 1H), 8.2 (s, 1H). The obtained spectroscopic data are in accordance with those reported in the literature.<sup>1</sup>

*ethyl 2-(4-cyanopyridin-3-yl)acetate (8.3)*



KCN solution (3.55 g, 54.5 mmol) in water (20 mL) was added dropwise for 20 minutes to a solution of **8.2** (18.37, 54.5 mmol) in EtOH:H<sub>2</sub>O (7:3, 30 mL) at 50 °C. After 1h, the reaction mixture was poured in ice and extracted with DCM (3x30), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The product was purified by Flash chromatography (Hexane – ethyl acetate, 6:4) to give 7.14 g of **8.3** (69%) of a dark orange oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.24 (t, *J* = 6 Hz, 3H), 3.82 (s, 2H), 4.45 (q, *J* = 6Hz, 2H), 7.5 (d, *J* = 2Hz, 1H), 8.65 (d, *J* = 6Hz, 1H), 8.68 (s, 1H). IR (cm<sup>-1</sup>): 2355, 1732, 1166, 1024, 773, 769, 578. HRMS (EI) *m/z* [M<sup>+</sup>] calcd for C<sub>10</sub>H<sub>11</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup>: 191.0815; found: 191.0831. The obtained spectroscopic data are in accordance with those reported in the literature.<sup>1</sup>


#### 1,4-dihydro-2,6-naphthyridin-3(2H)-one (**8.4**)



A solution of **8.3** (2.79 g, 14.63 mmol) in acetic acid : ethanol (150 mL, 1: 4) was hydrogenated by 10% Pd/C (300 mg) and H<sub>2</sub> balloons. The reaction was stirred for 24 h at 50 °C. The reaction was filtered through celite, and the residue washed with hot acetic acid (3 x 10 mL). The solution was evaporated under reduced pressure, the residue was poured into a 10% aqueous K<sub>2</sub>CO<sub>3</sub> solution and extracted with ethyl acetate (6x20mL). The crude product was purified by flash column chromatography (ethyl acetate), 1.77 g of **8.4** (82%) as a light brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 1.24 (t, *J* = 6 Hz, 3H), 3.82 (s, 2H), 4.45 (q, *J* = 6Hz, 2H), 7.5 (d, *J* = 2Hz, 1H), 8.65 (d, *J* = 6Hz, 1H), 8.68 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 32.4, 44.5, 120.5, 127.6, 140.3, 146.8, 147.8, 176.2. IR (cm<sup>-1</sup>): 3398, 2357, 1647, 1217, 1020, 771, 667, 576. HRMS (EI) *m/z* [M<sup>+</sup>] calcd for C<sub>8</sub>H<sub>9</sub>N<sub>2</sub>O<sup>+</sup>:149,0709; found: 149,0711. The obtained spectroscopic data are in accordance with those reported in the literature.<sup>1</sup>


#### 2,6-naphthyridin-3-ol (**2**)






Activated charcoal (640 mg) was added to a solution of **6.4** (6.4 g, 44 mmol) in xylene (200 mL) at 120 °C under an oxygen saturated atmosphere. The reaction was kept under stirring for 48 h. The reaction was filtered through celite and washed with MeOH. The solvent was removed under reduced pressure and the product was purified by flash chromatography (ethyl acetate— methanol, 9: 1) resulting in 2.89 g (45%) of a yellow solid. The obtained spectroscopic data are in accordance with those reported in the literature.<sup>1</sup>

*5-methoxy-1H-pyrazolo [3,4-c] pyridine (5)*




**4** (2 g, 17.3 mmol) was added to a round bottom flask equipped with a rubber septum. The flask was purged with N<sub>2</sub> and dry DCM (20 mL) was added. Acetic anhydride (1.7 mL, 19.4 mmol) was added and the reaction was stirred at room temperature. After 2 hours, NaNO<sub>2</sub> (7 g, 101 mmol) and acetic anhydride (6.5 mL, 69.4 mmol) were added to the reaction mixture. The reaction was kept under vigorous stirring at room temperature for 5 hours. Thereafter, DCM was removed under reduced pressure and the residue was suspended in toluene (50 mL), the reaction mixture was stirred for 1h at 110 °C. The solvent was removed under reduced pressure, and the residue was dissolved in 1 mL of concentrated aqueous HCl solution (20 mL) and stirred for 1h at 50 °C. The mixture was cooled to room temperature and basified with 1M NaOH<sub>aq</sub> to pH 8-9, extracted with chloroform (4 x 40 mL), the organic phase was dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. The product was purified by flash chromatography (Hexane— ethyl acetate, 2 : 1) yielding 600 mg of **5** (48%) as an orange solid. The obtained spectroscopic data are in accordance with those reported in the literature.<sup>1</sup>

### General procedure for one-pot to 1H-indazole




*o*-toluidine (400 μL, 3.72 mmol) was added to a round-bottom flask via syringe and fitted with a rubber septum. The flask was purged with nitrogen and dry DCM (10 mL) was added. Acetic anhydride (2 mL, 18.2 mmol) was added and the reaction was stirred at room temperature for 1 hour and monitored by LCMS. After the total consumption of the amine, NaNO<sub>2</sub> (136 mg, 26 mmol) and acetic anhydride (2 mL, 18.2 mmol) were added to the reaction mixture. The reaction was left under vigorous stirring at room temperature for 5 hours. After that, the DCM was removed under reduced pressure and the residue was suspended in toluene (20 mL), the reaction mixture was stirred for 1h at 110 °C. The solvent was removed under reduced pressure, and the residue was solved in 1M HCl<sub>aq.</sub> (20 mL) and stirred for 2h at 50 °C. The mixture was cooled to room temperature and basified with saturated aqueous solution NaHCO<sub>3</sub> to pH 8-9, then the mixture was extracted with chloroform (3x50mL). The organic phase was dried over MgSO<sub>4</sub> and the solvent removed under reduced pressure. The product was purified by Flash chromatography (Hexane - ethyl acetate, 2:1) to give 179 mg of indazole (81%, orange powder). The spectral data are consistent with those reported in the literature.<sup>6</sup>

### 1-tosyl-1H-pyrazole (**17**)




202 mg, yield 89% as yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.09 (d, *J* = 2.7 Hz, 1H), 7.87 (d, *J* = 8.4 Hz, 2H), 7.69 (d, *J* = 0.9 Hz, 1H), 7.30 (d, *J* = 8.0 Hz, 2H), 6.37 (dd, *J* = 2.7, 1.6 Hz, 1H), 2.38 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 145.9, 145.2, 133.9, 131.1, 130.1, 128.1, 108.8, 77.1, 21.7. The spectral data are consistent with those reported in the literature.<sup>7</sup>

### 1-tosyl-1H-indole (**18**)



178 mg, yield 81% as white solid. m.p. 94 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  2.40 (s, 3H), 6.65 (d,  $J = 3.2$  Hz, 1H), 7.33 – 7.28 (m, 2H), 7.21 (t,  $J = 6.8$  Hz, 1H), 7.30 (t,  $J = 7.6$  Hz, 1H), 7.51 (d,  $J = 7.6$  Hz, 1H), 7.56 (d,  $J = 3.6$  Hz, 1H), 7.88 (d,  $J = 8.5$  Hz, 2H), 7.97 (d,  $J = 8.0$  Hz, 1H). The spectral data are consistent with those reported in the literature.<sup>8</sup>

#### 1-tosyl-1H-indazole (19)




242 mg, yield 89% as yellowish solid. m.p. 102 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.23 (dt,  $J = 8.5, 0.9$  Hz, 1H), 8.20 (d,  $J = 0.9$  Hz, 1H), 7.92 – 7.86 (m, 2H), 7.71 (dt,  $J = 8.0, 1.1$  Hz, 1H), 7.58 (ddd,  $J = 8.4, 7.1, 1.2$  Hz, 1H), 7.34 (ddd,  $J = 8.0, 7.1, 0.9$  Hz, 1H), 7.30 – 7.20 (m, 2H), 2.37 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  145.4, 141.3, 140.3, 134.6, 129.8, 129.2, 127.5, 125.8, 124.2, 121.3, 113.2, 21.6. The spectral data are consistent with those reported in the literature.<sup>9</sup>

#### REFERENCES:


1. Silva Junior, P. E.; Rezende, L. C. D.; Gimenes, J. P.; Maltarollo, V. G.; Dale, J.; Trossini, G. H. G.; Emery, F. S.; Ganesan, A., *Rsc Advances* **2016**, *6* (27), 22777-22780.
2. Krasnokutskaya, E. A.; Semenischeva, N. I.; Filimonov, V. D.; Knochel, P., *Synthesis-Stuttgart* **2007**, (1), 81-84.
3. Ke, J.; He, C.; Liu, H. Y.; Xu, H.; Lei, A. W. *Chemical Communications* **2013**, *49* (60), 6767-6769.
4. Davis, O. A.; Croft, R. A.; Bull, J. A., *Chemical Communications* **2015**, *51* (84), 15446-15449.
5. Fumagalli, F.; Emery, F. D., *Journal of Organic Chemistry* **2016**, *81* (21), 10339-10347.
6. Kumar, M. R.; Park, A.; Park, N.; Lee, S., *Organic Letters* **2011**, *13* (13), 3542-3545.
7. Yotphan, S.; Sumunnee, L.; Beukeaw, D.; Buathongjan, C.; Reutrakul, V., *Organic & Biomolecular Chemistry* **2016**, *14* (2), 590-597.
8. Youn, S. W.; Lee, S. R.; Kim, Y. A.; Kang, D. Y.; Jang, M. J., *Chemistryselect* **2016**, *1* (18), 5749-5757.
9. Tang, M.; Kong, Y. F.; Chu, B. J.; Feng, D., *Advanced Synthesis & Catalysis* **2016**, *358* (6), 926-939.

### 3. NMR-SPECTRA


<sup>1</sup>H-NMR – 400 MHz in Methanol-d<sub>4</sub>: 1H-Pyrazolo[3,4-c]pyridin-5-ol (**1**)




<sup>13</sup>C NMR - 101 MHz in Methanol-d<sub>4</sub>: 1H-Pyrazolo[3,4-c]pyridin-5-ol (**1**)




$^1\text{H-NMR}$  – 300 MHz in  $\text{CDCl}_3$ : 2,6-naphthyridin-3-yl trifluoromethanesulfonate (**9**)




$^{13}\text{C-NMR}$  – 101 MHz in  $\text{CDCl}_3$ : 2,6-naphthyridin-3-yl trifluoromethanesulfonate (**9**)




$^1\text{H-NMR}$  – 300 MHz in  $\text{CDCl}_3$ : 3 - ((3-methylbut-2-en-1-yl) oxy) -2,6-naphthyridine (**10**)




<sup>13</sup>C-NMR – 75 MHz in CDCl<sub>3</sub>: 3-((3-methylbut-2-en-1-yl)oxy)-2,6-naphthyridine (**10**)



$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) - 5-methoxy-1H-pyrazolo [3,4-c] pyridine (5)




$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ) - 5-methoxy-1H-pyrazolo [3,4-c] pyridine (5)







<sup>1</sup>H NMR (300 MHz - CDCl<sub>3</sub>): 5-methoxy-1-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**15c**)




<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 5-methoxy-1-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**15c**)




<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 5-methoxy-1-tosyl-1H-pyrazolo[3,4-c]pyridine (**11**)




<sup>13</sup>C-NMR - 101 MHz in CDCl<sub>3</sub>: 5-methoxy-1-tosyl-1H-pyrazolo[3,4-c]pyridine (**11**)




<sup>1</sup>H-NMR – 400 MHz in DMSO-d<sub>6</sub>: 2,6-naphthyridin-3-ol (**2**)




<sup>13</sup>C NMR - 101 MHz in DMSO-d<sub>6</sub>: 2,6-naphthyridin-3-ol (**2**)




<sup>1</sup>H-NMR – 300 MHz in DMSO-d<sub>6</sub>: 4-(4-methoxyphenyl)-2,6-naphthyridin-3-ol (**12a**)




<sup>13</sup>C NMR - 101 MHz in DMSO-d<sub>6</sub>: 4-(4-methoxyphenyl)-2,6-naphthyridin-3-ol (**12a**)




<sup>1</sup>H-NMR – 300 MHz in DMSO-d<sub>6</sub>: 4-(4-(trifluoromethyl)phenyl)-2,6-naphthyridin-3-ol (**12b**)



<sup>13</sup>C NMR - 101 MHz in DMSO-d<sub>6</sub>: 4-(4-(trifluoromethyl)phenyl)-2,6-naphthyridin-3-ol (**12b**)




HSQC- 600 MHz in DMSO-d<sub>6</sub>: 4-(4-(trifluoromethyl)phenyl)-2,6-naphthyridin-3-ol (**12b**)








HMBC- 600 MHz in DMSO-d<sub>6</sub>: 4-(4-(trifluoromethyl)phenyl)-2,6-naphthyridin-3-ol (**12b**)




<sup>1</sup>H-NMR – 300 MHz in DMSO-d<sub>6</sub>: 4-(3-hydroxy-2,6-naphthyridin-4-yl)benzotrile (**12c**)






<sup>13</sup>C NMR - 101 MHz in DMSO-d<sub>6</sub>: 4-(4-chlorophenyl)-2,6-naphthyridin-3-ol (**12d**)




<sup>1</sup>H-NMR – 600 MHz in DMSO-d<sub>6</sub>: 4-(2,4-dichlorophenyl)-2,6-naphthyridin-3-ol (**12e**)

PS59 - 600  
AK opatz  
Name silva  
Code ps59  
h1.tci DMSO (C:\Bruker\av3-600\av600) nmrsu 6




<sup>13</sup>C NMR - 150 MHz in DMSO-d<sub>6</sub>: 4-(2,4-dichlorophenyl)-2,6-naphthyridin-3-ol (**12e**)


PSS9 - 600  
AK opatz  
Name silva  
Code ps59  
c13.tcf DMSO (C:\Bruker\av3-600\av600) nmsu 6




HSQC - 600 MHz in DMSO-d<sub>6</sub>: 4-(2,4-dichlorophenyl)-2,6-naphthyridin-3-ol (**12e**)



HMBC - 600 MHz in DMSO-d<sub>6</sub>: 4-(2,4-dichlorophenyl)-2,6-naphthyridin-3-ol (**12e**)




<sup>1</sup>H-NMR – 300 MHz in MeO-d<sub>4</sub>: 5-methoxy-4-phenyl-1H-pyrazolo[3,4-c]pyridine (**13**)




$^1\text{H-NMR}$  – 75 MHz in  $\text{MeO-d}_4$ : 5-methoxy-4-phenyl-1H-pyrazolo[3,4-c]pyridine (**13**)

shai634\_210121







<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 5-methoxy-1-(methylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**15a**)




<sup>13</sup>C-NMR - 101 MHz in CDCl<sub>3</sub>: 5-methoxy-1-(methylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**15a**)




<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 5-methoxy-1-(naphthalen-2-ylsulfonyl)-1H-pyrazolo[3,4-c]pyridine  
(15b)




<sup>13</sup>C NMR - 101 MHz in CDCl<sub>3</sub>: 5-methoxy-1-(naphthalen-2-ylsulfonyl)-1H-pyrazolo[3,4-c]pyridine  
(15b)




<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 5-methoxy-1-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**15c**)




<sup>13</sup>C NMR - 101 MHz in CDCl<sub>3</sub>: 5-methoxy-1-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**15c**)




<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 1-((4-bromophenyl)sulfonyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridine (15d)




<sup>13</sup>C NMR - 101 MHz in CDCl<sub>3</sub>: 1-((4-bromophenyl)sulfonyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridine (15d)




$^1\text{H-NMR}$  – 400 MHz in  $\text{CDCl}_3$ : 5-methoxy-1-((2,4,6-triisopropylphenyl)sulfonyl)-1H-pyrazolo[3,4-c]pyridine (**15e**)




$^{13}\text{C-NMR}$  - 101 MHz in  $\text{CDCl}_3$ : 5-methoxy-1-((2,4,6-triisopropylphenyl)sulfonyl)-1H-pyrazolo[3,4-c]pyridine (**15e**)




$^1\text{H-NMR}$  – 400 MHz in  $\text{CDCl}_3$ : 5-methoxy-3-tosyl-1H-pyrazolo[3,4-c]pyridine (**14**)




$^{13}\text{C-NMR}$  - 101 MHz in  $\text{CDCl}_3$ : 5-methoxy-3-tosyl-1H-pyrazolo[3,4-c]pyridine (**14**)



<sup>1</sup>H-NMR – 300 MHz in CDCl<sub>3</sub>: 5-methoxy-3-(naphthalen-2-ylsulfonyl)-1H-pyrazolo[3,4-c]pyridine  
(16b)




$^{13}\text{C}$  NMR - 75 MHz in  $\text{CDCl}_3$ : 5-methoxy-3-(naphthalen-2-ylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**16b**)




$^1\text{H}$ -NMR – 400 MHz in  $\text{CDCl}_3$ : 5-methoxy-3-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**16c**)







<sup>13</sup>C NMR - 101 MHz in CDCl<sub>3</sub>; 5-methoxy-3-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridine (**16c**)




<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 3-((4-bromophenyl)sulfonyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridine  
(16d)




<sup>13</sup>C NMR - 101 MHz in CDCl<sub>3</sub>: 3-((4-bromophenyl)sulfonyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridine  
(16d)




$^1\text{H-NMR}$  – 400 MHz in  $\text{CDCl}_3$ : 5-methoxy-3-((2,4,6-triisopropylphenyl)sulfonyl)-1H-pyrazolo[3,4-c]pyridine (**16e**)



$^{13}\text{C-NMR}$  - 101 MHz in  $\text{CDCl}_3$ : 5-methoxy-3-((2,4,6-triisopropylphenyl)sulfonyl)-1H-pyrazolo[3,4-c]pyridine (**16e**)




<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 1-tosyl-1H-pyrazole (17)




<sup>13</sup>C NMR - 101 MHz in CDCl<sub>3</sub>: 1-tosyl-1H-pyrazole (**17**)


qhm479




<sup>1</sup>H-NMR – 400 MHz in CDCl<sub>3</sub>: 1-tosyl-1H-indazole (19)




<sup>13</sup>C NMR - 101 MHz in CDCl<sub>3</sub>: 1-tosyl-1H-indazole (19)



<sup>1</sup>H-NMR – 300 MHz in CDCl<sub>3</sub>: 3-tosyl-1H-indazole (**20**)




$^{13}\text{C}$  NMR - 75 MHz in  $\text{CDCl}_3$ : 3-tosyl-1H-indazole (**20**)







$^1\text{H-NMR}$  – 400 MHz in  $\text{CD}_3\text{OD}$ : 3-tosyl-1H-pyrazolo[3,4-c]pyridin-5-ol (**21**)




$^{13}\text{C-NMR}$  - 101 MHz in  $\text{CD}_3\text{OD}$ : 3-tosyl-1H-pyrazolo[3,4-c]pyridin-5-ol (**21**)




HMBC- 400 MHz in CD<sub>3</sub>OD: 3-tosyl-1H-pyrazolo[3,4-c]pyridin-5-ol (**21**)




1-ethyl-5-methoxy-3-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridine <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) (22)



1-ethyl-5-methoxy-3-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridine. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) (22)



2-(5-methoxy-3-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetonitrile.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) (**23**)



2-(5-methoxy-3-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetonitrile.  $^1\text{H}$   $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ) (**23**)

shai496\_200120

